Keynote-495/Keyimpact: A Randomized, Biomarker-Directed, Phase Ii Trial Of Pembrolizumab-Based Therapy For Non-Small Cell Lung Cancer (Nsclc)M. Gutierrez,W-S. Lam,M. D. Hellmann, M. A. Gubens, C. Aggarwal,D. S. W. Tan, E. Felip, J. W. Y. Chiu, J. S. Lee,J. C-H. Yang,E. B. Garon, A. Basso, H. Ma,L. Fong, A. Snyder,J. Yuan,R. S. HerbstANNALS OF ONCOLOGY（2019）引用 3|浏览34暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
